Concord Biotech Limited

Concord Biotech Limited company information, Employees & Contact Information

Concord Biotech Limited is an R&D based Biotechnology company, having focus on the fermentation, semi-synthetic and synthesis based products. Since its inception in 2000, Concord has recorded an excellent growth through diversification and process improvements. Having state-of-the-art US FDA & EUGMP approved facility; Concord is a professionally managed globally recognised supplier of fermentation based API’s and enzyme & offers services in biotechnology area like strain improvement & contract fermentation/ manufacturing. The existing portfolio of products includes API’s in the immunosuppressant, antibiotic, Oncology , Anti-Obesity, hypolipemic segments and enzymes. However, with the expertise in the field of biotechnology and chemistry, the R&D team at Concord is working towards adding new products to the product basket.
Looking for a particular Concord Biotech Limited employee's phone or email?

Concord Biotech Limited Questions

News

Concord Biotech Targets 25% Annual Growth, Releases Q1 FY26 Earnings Call Recording - scanx.trade

Concord Biotech Targets 25% Annual Growth, Releases Q1 FY26 Earnings Call Recording scanx.trade

Briefs: J B Chemicals and Pharmaceuticals, Concord Biotech and Gland Pharma - Indian Pharma Post

Briefs: J B Chemicals and Pharmaceuticals, Concord Biotech and Gland Pharma Indian Pharma Post

Concord Biotech share price pops 6% on healthy Q4 nos; profit zooms 48% YoY - Business Standard

Concord Biotech share price pops 6% on healthy Q4 nos; profit zooms 48% YoY Business Standard

Stocks to buy for short term: From UCO Bank to Concord Biotech— Jigar Patel of Anand Rathi recommends 3 shares - Mint

Stocks to buy for short term: From UCO Bank to Concord Biotech— Jigar Patel of Anand Rathi recommends 3 shares Mint

Concord Biotech Reports Q1FY26 Results: Revenue Down 5%, EBITDA Declines 24% - scanx.trade

Concord Biotech Reports Q1FY26 Results: Revenue Down 5%, EBITDA Declines 24% scanx.trade

Concord Biotech shares tumble 16% after weak Q3 earnings - The Economic Times

Concord Biotech shares tumble 16% after weak Q3 earnings The Economic Times

Concord Biotech gains after successful EU-GMP inspection at Limbassi facility - Business Standard

Concord Biotech gains after successful EU-GMP inspection at Limbassi facility Business Standard

Concord Biotech invests $10 lakh in Palvella Therapeutics - Zee Business

Concord Biotech invests $10 lakh in Palvella Therapeutics Zee Business

Concord Biotech shares jump 6 per cent; here's what is fueling the gains - Business Standard

Concord Biotech shares jump 6 per cent; here's what is fueling the gains Business Standard

USFDA inspection at Concord Biotech’s API facility at Dholka - Indian Pharma Post

USFDA inspection at Concord Biotech’s API facility at Dholka Indian Pharma Post

Sudhir Vaid, Chairman & Managing Director, Concord Biotech - India Infoline

Sudhir Vaid, Chairman & Managing Director, Concord Biotech India Infoline

Concord Biotech stock surges 12% on high volumes; climbs fresh peak - Moneycontrol

Concord Biotech stock surges 12% on high volumes; climbs fresh peak Moneycontrol

Quadria Capital to sell stake in API maker Concord Biotech - VCCircle

Quadria Capital to sell stake in API maker Concord Biotech VCCircle

Here's why Concord Biotech shares gained 5% in trade on April 9; details - Business Standard

Here's why Concord Biotech shares gained 5% in trade on April 9; details Business Standard

Concord Biotech IPO subscribed 2.72 times on day 2; retail portion booked 2.26 times - Mint

Concord Biotech IPO subscribed 2.72 times on day 2; retail portion booked 2.26 times Mint

Concord Biotech makes a strong debut on Dalal Street; what should investors do? - Zee Business

Concord Biotech makes a strong debut on Dalal Street; what should investors do? Zee Business

Concord Biotech shares list at a healthy premium. What should investors do? - The Economic Times

Concord Biotech shares list at a healthy premium. What should investors do? The Economic Times

Concord Biotech shares plunge 16% on reporting Q3 results; PAT down 2% YoY - Business Standard

Concord Biotech shares plunge 16% on reporting Q3 results; PAT down 2% YoY Business Standard

Concord Biotech IPO: What does GMP signal about the listing? - Mint

Concord Biotech IPO: What does GMP signal about the listing? Mint

Concord Biotech shares hit all time high; Antique Broking reiterates 'Buy' - Business Standard

Concord Biotech shares hit all time high; Antique Broking reiterates 'Buy' Business Standard

Jhunjhunwala family-backed Concord Biotech gains 27% on market debut - Business Standard

Jhunjhunwala family-backed Concord Biotech gains 27% on market debut Business Standard

Concord Biotech IPO Date, Review, Price, Allotment Details - IPO Watch

Concord Biotech IPO Date, Review, Price, Allotment Details IPO Watch

Concord Biotech IPO GMP, Price, Allotment, Profit Estimate 2023 - IPO Central

Concord Biotech IPO GMP, Price, Allotment, Profit Estimate 2023 IPO Central

Concord Biotech, backed by Rakesh Jhunjhunwala's firm, targets August IPO launch at up to $1 bn valuation - Moneycontrol

Concord Biotech, backed by Rakesh Jhunjhunwala's firm, targets August IPO launch at up to $1 bn valuation Moneycontrol

Concord Biotech IPO: Understanding Business Model & Growth Plans, Key Insights from Management - Zee Business

Concord Biotech IPO: Understanding Business Model & Growth Plans, Key Insights from Management Zee Business

Concord Biotech IPO GMP, Grey Market Premium Today - IPO Watch

Concord Biotech IPO GMP, Grey Market Premium Today IPO Watch

Top Concord Biotech Limited Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant